Cargando…
Advances in cancer immunotherapy 2019 – latest trends
Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. The two main drivers behind this success are checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells. This review...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585101/ https://www.ncbi.nlm.nih.gov/pubmed/31217020 http://dx.doi.org/10.1186/s13046-019-1266-0 |
_version_ | 1783428640127582208 |
---|---|
author | Kruger, Stephan Ilmer, Matthias Kobold, Sebastian Cadilha, Bruno L. Endres, Stefan Ormanns, Steffen Schuebbe, Gesa Renz, Bernhard W. D’Haese, Jan G. Schloesser, Hans Heinemann, Volker Subklewe, Marion Boeck, Stefan Werner, Jens von Bergwelt-Baildon, Michael |
author_facet | Kruger, Stephan Ilmer, Matthias Kobold, Sebastian Cadilha, Bruno L. Endres, Stefan Ormanns, Steffen Schuebbe, Gesa Renz, Bernhard W. D’Haese, Jan G. Schloesser, Hans Heinemann, Volker Subklewe, Marion Boeck, Stefan Werner, Jens von Bergwelt-Baildon, Michael |
author_sort | Kruger, Stephan |
collection | PubMed |
description | Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. The two main drivers behind this success are checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells. This review summarizes seminal findings from clinical and translational studies recently presented or published at important meetings or in top-tier journals, respectively. For checkpoint blockade, current studies focus on combinational approaches, perioperative use, new tumor entities, response prediction, toxicity management and use in special patient populations. Regarding cellular immunotherapy, recent studies confirmed safety and efficacy of CAR T cells in larger cohorts of patients with acute lymphoblastic leukemia or diffuse large B cell lymphoma. Different strategies to translate the striking success of CAR T cells in B cell malignancies to other hematological and solid cancer types are currently under clinical investigation. Regarding the regional distribution of registered clinical immunotherapy trials a shift from PD-1 / PD-L1 trials (mainly performed in the US and Europe) to CAR T cell trials (majority of trials performed in the US and China) can be noted. |
format | Online Article Text |
id | pubmed-6585101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65851012019-06-27 Advances in cancer immunotherapy 2019 – latest trends Kruger, Stephan Ilmer, Matthias Kobold, Sebastian Cadilha, Bruno L. Endres, Stefan Ormanns, Steffen Schuebbe, Gesa Renz, Bernhard W. D’Haese, Jan G. Schloesser, Hans Heinemann, Volker Subklewe, Marion Boeck, Stefan Werner, Jens von Bergwelt-Baildon, Michael J Exp Clin Cancer Res Review Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. The two main drivers behind this success are checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells. This review summarizes seminal findings from clinical and translational studies recently presented or published at important meetings or in top-tier journals, respectively. For checkpoint blockade, current studies focus on combinational approaches, perioperative use, new tumor entities, response prediction, toxicity management and use in special patient populations. Regarding cellular immunotherapy, recent studies confirmed safety and efficacy of CAR T cells in larger cohorts of patients with acute lymphoblastic leukemia or diffuse large B cell lymphoma. Different strategies to translate the striking success of CAR T cells in B cell malignancies to other hematological and solid cancer types are currently under clinical investigation. Regarding the regional distribution of registered clinical immunotherapy trials a shift from PD-1 / PD-L1 trials (mainly performed in the US and Europe) to CAR T cell trials (majority of trials performed in the US and China) can be noted. BioMed Central 2019-06-19 /pmc/articles/PMC6585101/ /pubmed/31217020 http://dx.doi.org/10.1186/s13046-019-1266-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Kruger, Stephan Ilmer, Matthias Kobold, Sebastian Cadilha, Bruno L. Endres, Stefan Ormanns, Steffen Schuebbe, Gesa Renz, Bernhard W. D’Haese, Jan G. Schloesser, Hans Heinemann, Volker Subklewe, Marion Boeck, Stefan Werner, Jens von Bergwelt-Baildon, Michael Advances in cancer immunotherapy 2019 – latest trends |
title | Advances in cancer immunotherapy 2019 – latest trends |
title_full | Advances in cancer immunotherapy 2019 – latest trends |
title_fullStr | Advances in cancer immunotherapy 2019 – latest trends |
title_full_unstemmed | Advances in cancer immunotherapy 2019 – latest trends |
title_short | Advances in cancer immunotherapy 2019 – latest trends |
title_sort | advances in cancer immunotherapy 2019 – latest trends |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585101/ https://www.ncbi.nlm.nih.gov/pubmed/31217020 http://dx.doi.org/10.1186/s13046-019-1266-0 |
work_keys_str_mv | AT krugerstephan advancesincancerimmunotherapy2019latesttrends AT ilmermatthias advancesincancerimmunotherapy2019latesttrends AT koboldsebastian advancesincancerimmunotherapy2019latesttrends AT cadilhabrunol advancesincancerimmunotherapy2019latesttrends AT endresstefan advancesincancerimmunotherapy2019latesttrends AT ormannssteffen advancesincancerimmunotherapy2019latesttrends AT schuebbegesa advancesincancerimmunotherapy2019latesttrends AT renzbernhardw advancesincancerimmunotherapy2019latesttrends AT dhaesejang advancesincancerimmunotherapy2019latesttrends AT schloesserhans advancesincancerimmunotherapy2019latesttrends AT heinemannvolker advancesincancerimmunotherapy2019latesttrends AT subklewemarion advancesincancerimmunotherapy2019latesttrends AT boeckstefan advancesincancerimmunotherapy2019latesttrends AT wernerjens advancesincancerimmunotherapy2019latesttrends AT vonbergweltbaildonmichael advancesincancerimmunotherapy2019latesttrends |